Search Results - "Belohlavkova, P"

Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome by Belohlavkova, P, Vrbacky, F, Smolej, L, Radocha, J, Lanska, M, Visek, B, Kupsa, T, Zavrelova, A, Zak, P

“…In the present study, we retrospectively analysed the results of HSCT in 47 consecutive patients with MDS diagnosed at our department between 2002 and 2019,…”
Get full text

103 AZACITIDINE TREATMENT OF HIGH RISK MDS AND AML, ANALYSIS OF LONG RESPONDING PATIENTS AND PROGNOSTIC FACTORS OF OVERALL SURVIVAL, CZECH MDS GROUP EXPERIENCE by Jonasova, A, Cermak, J, Cervinek, L, Belohlavkova, P, Cerna, O, Kacmarova, K, Janousova, E

Get full text

Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia by Voglova, J, Muzik, J, Faber, E, Zackova, D, Klamova, H, Steinerova, K, Michalovicova, Z, Demitrovicova, L, Cmunt, E, Novakova, L, Tothova, E, Belohlavkova, P, Mayer, J, Indrak, K

“…Tyrosine kinase inhibitors (TKI) have completely changed the prognosis of patients with Ph+ chronic myeloid leukemia (CML). The occurrence of a second…”
Get more information

211 Deferasirox vs. deferiprone treatment in iron overloaded patients with myelodysplastic syndrome – a study on 113 patients with low-risk MDS by Cermak, J, Jonasova, A, Vondrakova, J, Cervinek, L, Belohlavkova, P, Sponerova, D, Novakova, L, Walterova, L, Neuwirtova, R

Get full text

175 Czech MDS Group experience with azacitidine in treatment of high risk MDS and AML patients by Jonasova, A, Cermak, J, Cervinek, L, Novakova, L, Vondrakova, J, Belohlavkova, P, Sykora, M, Seifertova, N, Walterova, L, Libiger, J, Michalova, K, Zemanova, Z, Brezinova, J, Kacmarova, K, Klapka, R

Get full text

274 The response of FLi1, EKLF, TP53 (p53), PU.1, MDM2 gene expression in 5q- syndrome to lenalidomide treatment by Jonasova, A, Fuchs, O, Vostry, M, Holicka, M, Kostecka, A, Cermak, J, Caniga, M, Kobylka, P, Siskova, M, Cervinek, L, Belohlavkova, P, Sykora, M, Zemanova, Z, Michalova, K, Brezinova, J, Neuwirtova, R

Get full text

247 miRNA expression profiling in 5q- syndrome patients treated with lenalidomide by Krejcik, Z, Merkerova, M. Dostalova, Belickova, M, Cermak, J, Michalova, K, Zemanova, Z, Cervinek, L, Belohlavkova, P, Sykora, M, Libiger, J, Neuwirtova, R, Jonasova, A

Get full text

301 Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q- MDS (IPSS low and Intermediate-1) by Jonasova, A, Cermak, J, Vondrakova, J, Siskova, M, Hochova, I, Kadlckova, E, Cerna, O, Sykora, M, Vozobulova, V, Seifertova, N, Michalova, K, Zemanova, Z, Brezinova, J, Belohlavkova, P, Neuwirtova, R

Get full text

228 Lenalidomide treatment of patients with 5q- syndrome affects genes located in the TNF pathway by Belickova, M, Cermak, J, Vesela, J, Cechova, E, Dostalova-Merkerova, M, Krejcik, Z, Michalova, K, Zemanova, Z, Cervinek, L, Belohlavkova, P, Sykora, M, Libiger, J, Neuwirtova, R, Jonasova, A

Get full text

P075 Characteristics of patients with therapy-related myelodysplastic syndrome by Belohlavkova, P, Voglova, J, Neuwirtova, R, Krejcova, H, Cermak, J, Vondrakova, J, Vozobulova, V, Krejci, M, Muzik, J

Get full text

P081 The questions on megakaryopoiesis in MDS patients with del(5q) by Neuwirtova, R, Jonasova, A, Cermak, J, Vondrakova, J, Hochova, I, Jungova, A, Belohlavkova, P, Siskova, M, Kadlckova, E, Cerna, O, Smolikova, A, Polonyova, E, Bruchova, H, Zemanova, Z, Mikulenkova, D

Get full text

PO015 Therapy-related MDS/AML after by Belohlavkova, P, Zavrelova, A, Zak, P, Cermanova, M, Belada, D, Voglova, J, Jebavy, L, Maly, J

Get full text

P08 - Topic: AS02-Epidemiology: TEN YEARS OF THE CZECH MDS REGISTRY: REAL LIFE DATA AND EXPERIENCES by Jonasova, A., Belohlavkova, P., Cervinek, L., Cermak, J., Dusilkova, N., Baranova, J.

Get full text

Topic: AS02-Epidemiology by Jonasova, A., Belohlavkova, P., Cervinek, L., Cermak, J., Dusilkova, N., Baranova, J.

Get full text

Is it Important to Perform Liver Biopsy After Allogeneic Transplantation? by Zak, P, Zavrelova, A, Cermanova, M, Jebavy, L, Belohlavkova, P

Get full text

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia – the Retrospective Analysis by Vondrakova, J, Belohlavkova, P, Zapletalova, J, Raida, L, Zak, P, Jebavy, L, Voglova, J, Zavrelova, A, Pikalova, Z, Skoumalova, I, Jarosova, M, Faber, E, Maly, J, Indrak, K

Get full text

334 The importance of prognostic parametres for the allogeneic transplantation course in patients with myelodysplastic syndromes and secondary acute leukemia by Vondráková, J, Bělohlávková, P, Zapletalová, J, Raida, L, Žák, P, Jebavý, L, Voglová, J, Zavřelová, A, Lánská, M, Pikalová, Z, Skoumalová, I, Jarošová, M, Faber, E, Malý, J, Indrák, K

Get full text

CO77 Impact of Imetelstat Treatment on PROs and Health Care Resource Utilization in Heavily Transfused Non-Del(5Q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents: IMerge Phase 3 Trial by Sekeres, M., Santini, V., Diez-Campelo, M., Komrokji, R., Fenaux, P., Savona, M., Madanat, Y., Valcárcel-Ferreiras, D., Illmer, T., Jonášová, A., Bělohlávková, P., Regnault, A., Creel, K., Sengupta, N., Sherman, L., Berry, T., Dougherty, S., Shah, S., Xia, Q., Sun, L., Wan, Y., Huang, F., Ikin, A., Navada, S., Feller, F., Zeidan, A., Platzbecker, U.

Get full text

Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome by Belohlavkova, P, Vrbacky, F, Smolej, L, Radocha, J, Lanska, M, Visek, B, Kupsa, T, Zavrelova, A, Zak, P

Get full text